Table 4 Hazard ratios (CCLG vs. GPOH) according to local treatment modality

No. events

 EFS

21

105

53

131

93

38

 OS

19

92

41

109

79

30

Unadjusted

 EFS

20 (2.64–161)

0.86 (0.58–1.26)

1.31 (0.76–2.25)

1.67 (1.05–2.66)

2.22 (0.81–6.07)

1.99 (1.05–3.78)

 OS

1.50 (0.56–3.96)

0.95 (0.63–1.44)

1.50 (0.81–2.80)

1.65 (1.00–2.74)

1.96 (0.72–5.37)

2.10 (1.02–4.30)

Adjusted for age, metastatic disease, primary site and histology

 EFS

53 (4.0–477)

0.92 (0.62–1.38)

1.24 (0.70–2.20)

1.82 (1.12–2.94)

2.40 (0.84–6.84)

2.50 (1.24–5.06)

 OS

2.09 (0.64–6.79)

1.06 (0.69–1.63)

1.41 (0.73–2.74)

1.81 (1.07–3.05)

2.21 (0.77–6.35)

2.76 (1.26–6.05)

Adjusted for age, metastatic disease, primary site, histology and time between the start of chemotherapy and starting local treatment

 EFS

0.91 (0.60–1.38)

1.24 (0.70–2.19)

1.61 (0.96–2.70)

1.98 (0.70–5.60)

2.83 (1.30–6.16)

 OS

1.04 (0.67–1.63)

1.43 (0.73–2.78)

1.68 (0.97–2.91)

1.94 (0.68–5.58)

3.39 (1.42–8.06)